Talphera
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Talphera sits in the top decile of US sponsors by registered trial count (#801 of 15,742 sponsors by registered trial count).
Talphera: 18 sponsored US clinical trials, 1 recruiting.
Talphera sponsors 18 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 17 completed. 7 of these trials are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Postoperative Pain, with 2 trials.
Top-decile sponsor footprint
Talphera ranks in the top decile of sponsors by registered trial count (#801 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
17 of 17 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
18 total, page 1 of 1
Nafamostat Efficacy in Phase 3 Registrational CRRT Study
NCT06150742
Study to Evaluate the Overall Performance of the Zalviso System™ (Sufentanil Sublingual Tablet System) 15 mcg
NCT02662764
A Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg in Patients With Post-Operative Pain
NCT02662556
Open-Label Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg for Acute Pain
NCT02447848
A Trial Evaluating the Efficacy and Safety of the Sublingual Sufentanil Tablet 30 mcg for Post-Operative Pain After Abdominal Surgery
NCT02356588
Pharmacokinetics of Sufentanil Sublingual Microtablet 30 mcg and 15 mcg in Healthy Subjects
NCT02082236
Single and Multiple Dose Pharmacokinetics of Sufentanil NanoTab
NCT01761565
Effect of Ketoconazole on Sufentanil NanoTab Pharmacokinetics
NCT01721070
Safety and Efficacy of Sufentanil NanoTab for Management of Acute Pain Following Bunionectomy
NCT01710345
Efficacy and Safety Trial to Evaluate the Sufentanil NanoTab® PCA System/15 mcg (Zalviso™) for Post-Operative Pain in Patients After Knee or Hip Replacement Surgery
NCT01660763
Effect of Delivery Route on PK of Sufentanil NanoTab
NCT01639729
A Multicenter, Randomized, Open-Label, Parallel-Group Trial to Compare the Efficacy and Safety of the Sufentanil NanoTab PCA System/15 mcg (Zalviso™)to Intravenous Patient-Controlled Analgesia With Morphine for the Treatment of Acute Post-Operative Pain
NCT01539538
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of the Sufentanil NanoTab PCA System/15 mcg (Zalviso™) for the Treatment of Post-Operative Pain in Patients After Open Abdominal Surgery
NCT01539642
A Study to Evaluate the Clinical Efficacy, Safety and Tolerability of ARX-F03 Sublingual Sufentanil/Triazolam NanoTab™ in Patients Undergoing an Elective Abdominal Liposuction Procedure
NCT00894699
An Open-Label Functionality, Safety and Efficacy Study in Patients Undergoing Elective Unilateral Knee Replacement
NCT00859313
A Study for the Evaluation of the Safety, Tolerability, and Efficacy of ARX-F02 (Sufentanil NanoTab) Compared to Placebo in the Treatment of Cancer Breakthrough Pain
NCT00833040
A Multicenter, Randomized, Placebo-Controlled Phase 2 Study to Evaluate the Clinical Efficacy, Safety, and Tolerability of ARX-F01 Sublingual Sufentanil in Patients Undergoing Major Abdominal Surgery
NCT00718081
A Multicenter, Randomized, Placebo-Controlled Phase 2 Study to Evaluate the Clinical Efficacy, Safety, and Tolerability of ARX-F01 Sublingual Sufentanil in Patients Undergoing Elective Unilateral Total Knee Replacement
NCT00612534
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 6 |
| Phase 3 | 7 |
Therapeutic Areas
What is open in the Talphera pipeline
1 recruiting of 18 indexed (6% open); 17 completed (94%).
Phase mix: 7 late (III/IV) vs 10 early (I/II) (balanced across stages).
Top condition: Postoperative Pain (2 trials), 6 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Talphera: open-pipeline peers nationwide
Peers matched on 18 registered trials and 6% open enrollment, not the therapeutic-area sidebar.
Talphera sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 18 trials (± recruiting share)
- ADC Therapeutics S.A. · 18 trials · 11% recruiting
- Akros Pharma · 18 trials · 0% recruiting
- AO Clinical Investigation and Publishing Documentation · 18 trials · 0% recruiting
- AO Innovation Translation Center · 18 trials · 33% recruiting
Sponsors near 6% open enrollment (± trial volume)
- Boston College · 6% recruiting · 18 trials
- CytoDyn · 6% recruiting · 18 trials
- Dendreon · 6% recruiting · 18 trials
- Intercept Pharmaceuticals · 6% recruiting · 18 trials
Related
What to do with this Talphera page
18 registered trials is a research-attention snapshot, not an endorsement of Talphera or any single study.
- 1 of Talphera's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Postoperative Pain is the condition Talphera studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Postoperative Pain trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Talphera pipeline card: 18 registered trials from official public datasets.Report a data error.